Cansino Biologics Inc (688185) - Total Liabilities

Latest as of December 2025: CN¥-4.93 Billion CNY ≈ $-721.61 Million USD

Based on the latest financial reports, Cansino Biologics Inc (688185) has total liabilities worth CN¥-4.93 Billion CNY (≈ $-721.61 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Cansino Biologics Inc (688185) net asset momentum to track the company's year-over-year net asset growth rate.

Cansino Biologics Inc - Total Liabilities Trend (2016–2025)

This chart illustrates how Cansino Biologics Inc's total liabilities have evolved over time, based on quarterly financial data. See 688185 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Cansino Biologics Inc Competitors by Total Liabilities

The table below lists competitors of Cansino Biologics Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Mesnac Co Ltd SHE:002073	China	CN¥13.87 Billion
IRB-Brasil Resseguros S.A. SA:IRBR3	Brazil	R$10.13 Billion
Clinica Baviera MC:CBAV	Spain	€130.65 Million
Sparekassen Sjaelland-Fyn A/S CO:SPKSJF	Denmark	Dkr30.11 Billion
Tian Jin Motor Dies Co Ltd SHE:002510	China	CN¥3.51 Billion
Corsair Gaming Inc NASDAQ:CRSR	USA	$516.53 Million
Kodiak AI, Inc. Common Stock NASDAQ:KDK	USA	$153.55 Million

Liability Composition Analysis (2016–2025)

This chart breaks down Cansino Biologics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Cansino Biologics Inc market cap and net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	3.55	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	-1.00	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	-0.69	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Cansino Biologics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Cansino Biologics Inc (2016–2025)

The table below shows the annual total liabilities of Cansino Biologics Inc from 2016 to 2025.

Year	Total Liabilities	Change
2025-12-31	CN¥-4.93 Billion ≈ $-721.61 Million	-261.78%
2024-12-31	CN¥3.05 Billion ≈ $446.06 Million	-24.39%
2023-12-31	CN¥4.03 Billion ≈ $589.91 Million	-4.55%
2022-12-31	CN¥4.22 Billion ≈ $618.01 Million	+26.97%
2021-12-31	CN¥3.33 Billion ≈ $486.74 Million	+391.17%
2020-12-31	CN¥677.22 Million ≈ $99.10 Million	+115.69%
2019-12-31	CN¥313.98 Million ≈ $45.95 Million	+6.96%
2018-12-31	CN¥293.56 Million ≈ $42.96 Million	+13.33%
2017-12-31	CN¥259.03 Million ≈ $37.90 Million	+131.90%
2016-12-31	CN¥111.70 Million ≈ $16.35 Million	--

About Cansino Biologics Inc

SHG:688185 China Drug Manufacturers - Specialty & Generic

Market Cap

$842.34 Million

CN¥5.76 Billion CNY

Market Cap Rank

#9652 Global

#2461 in China

Share Price

CN¥50.33

Change (1 day)

-1.78%

52-Week Range

CN¥47.90 - CN¥88.19

All Time High

CN¥773.75